PedAM
Pediatric Disease Annotations & Medicines
| Disease | diabetes mellitus, insulin-dependent |
| Symptom | C1393529|vascular complications |
| Sentences | 59 |
| PubMedID- 24083407 | Background: to examine the effects of physical activity on the development and progression of microvascular complications in patients with type 1 diabetes. |
| PubMedID- 20823346 | Low peripheral nerve conduction velocities and amplitudes are strongly related to diabetic microvascular complications in type 1 diabetes: the eurodiab prospective complications study. |
| PubMedID- 20969435 | The diabetes control and complications trial (dcct) demonstrated the importance of optimal glycemic control achieved through intensive insulin therapy in reducing the microvascular complications associated with type 1 diabetes. |
| PubMedID- 25848912 | Background: impaired regulation of extracellular matrix remodeling by matrix metalloproteinases (mmps) and tissue inhibitor of metalloproteinase (timp) may contribute to vascular complications in patients with type 1 diabetes. |
| PubMedID- 21437086 | The latest treatment recommendations3 suggest a target glycosylated hemoglobin (hba1c) level ≤7%, which has been shown to reduce microvascular complications of type 1 diabetes mellitus. |
| PubMedID- 21636794 | The epidemiology of diabetes interventions and complications (edic) study found that age levels from biopsied skin were predictive for the progression of microvascular complications in patients with type 1 diabetes (7,8). |
| PubMedID- 23882708 | Background: the diabetes control and complications trial (dcct)/epidemiology of diabetes interventions and complications(edic) studies have established multiyear mean hemoglobin a1c (hba1c) as predictive of microvascular complications in persons with type 1 diabetes. |
| PubMedID- 24072081 | Microvascular complications in adolescents with type 1 diabetes mellitus. |
| PubMedID- 22960236 | Does oxidized ldl contribute to atherosclerotic plaque formation and microvascular complications in patients with type 1 diabetes. |
| PubMedID- 22933438 | The diabetes control and complications trial (dcct) provided conclusive evidence that improving glycemic control minimizes the development of microvascular complications in patients with type 1 diabetes (1). |
| PubMedID- 26415611 | Erratum to: plasma levels of matrix metalloproteinase-2, -3, -10, and tissue inhibitor of metalloproteinase-1 are associated with vascular complications in patients with type 1 diabetes: the eurodiab prospective complications study. |
| PubMedID- 20692197 | Cardiovascular complications in type 1 diabetes mellitus. |
| PubMedID- 25954674 | Background: glycemic control prevents microvascular complications in patients with type i diabetes mellitus such as retinopathy, nephropathy and neuropathy that influences quality of life. |
| PubMedID- 26529311 | The dcct was designed to identify the relationship between glycemic control and microvascular complications associated with type 1 diabetes. |
| PubMedID- 19926157 | Aim: to analyze the prevalence of masked hypertension and its possible association with microvascular complications in patients with type 1 diabetes (t1d). |
| PubMedID- 25317238 | Studies have demonstrated the importance of endothelial dysfunction as an useful tool for identifying the risk of vascular complications in patients with type 1 diabetes mellitus, particularly as regards to renal impairment. |
| PubMedID- 25591852 | Objective: the objective of this study was to elucidate whether the degree of autonomic modulation is associated with the degree of microvascular complications in patients with type 1 diabetes. |
| PubMedID- 21249604 | This review also focuses on recent data from large prospective studies suggesting a strong association between procoagulant imbalance and development of chronic vascular complications in people with type 1 diabetes. |
| PubMedID- 20886054 | Intensive glycemic control delays and prevents microvascular and macrovascular complications of type 1 diabetes (t1dm) . |
| PubMedID- 25007947 | The effect of autoimmunity on the development time of microvascular complications in patients with type 1 diabetes mellitus. |
| PubMedID- 22275448 | High prevalence of microvascular complications in adults with type 1 diabetes and newly diagnosed celiac disease. |
| PubMedID- 25072271 | Intensive insulin therapy (iit) has been shown to reduce micro- and macrovascular complications in patients with type 1 diabetes mellitus (t1dm). |
| PubMedID- 20191079 | The dcct evaluated whether intensive antidiabetes treatment could decrease the frequency and severity of microvascular complications in patients with type 1 diabetes. |
| PubMedID- 21911774 | Abpm may be a useful method for detecting the macrovascular complications of type 1 diabetes. |
| PubMedID- 25948670 | Background: improved glycated hemoglobin (hb a1c) delays the progression of microvascular and macrovascular complications in individuals with type 1 diabetes (t1d). |
| PubMedID- 21568748 | The aim of the study was to assess the association between af and microvascular complications in type 1 diabetes mellitus (dm1). |
| PubMedID- 20153491 | Demonstration of increased toll-like receptor 2 and toll-like receptor 4 expression in monocytes of type 1 diabetes mellitus patients with microvascular complications. |
| PubMedID- 21705065 | Background: poor glycaemic control is associated with microvascular and macrovascular complications in type 1 diabetes, but whether glycaemic control is associated with heart failure in such patients is not known. |
| PubMedID- 24929955 | Serum uric acid predicts vascular complications in adults with type 1 diabetes: the coronary artery calcification in type 1 diabetes study. |
| PubMedID- 24165454 | In addition, familial risk factors related to all microvascular complications of type 1 diabetes have been reported . |
| PubMedID- 24458354 | The diabetes control and complications trial (dcct) (1983–1993) demonstrated that intensive therapy aimed at near-normal levels of glycemia (hba1c level) profoundly reduced the development and progression of microvascular complications in patients with type 1 diabetes compared with conventional therapy aimed at maintaining clinical well-being (8). |
| PubMedID- 23371411 | Interleukin 6 (il-6) plays an important role in the initiation and acceleration of chronic inflammation and could contribute to development of microvascular complications in patients with type 1 diabetes (dm1). |
| PubMedID- 21570646 | Background: several epidemiological studies showed a close association between metabolic control and microvascular complications in type 1 diabetes mellitus (t1dm). |
| PubMedID- 23216128 | Although bp lowering is an important goal for the management of diabetes, off-target actions to activate the raas may contribute to an observed lack of protection from cardiovascular complications in patients with type 1 diabetes with low sodium intake. |
| PubMedID- 23226632 | The diabetes control and complications trial (dcct) and the stockholm diabetes intervention study (sdis) showed that intensive therapy significantly reduced the incidence and progression of micro-vascular complications in patients with type 1 diabetes. |
| PubMedID- 25975731 | Glycated albumin and the risk of micro- and macrovascular complications in subjects with type 1 diabetes. |
| PubMedID- 21498084 | type 1 diabetes (t1dm) is associated with increased vascular complications and is a pro-inflammatory state. |
| PubMedID- 23877984 | To conclude, the current study provides new knowledge on the cerebrovascular complications in patients with type 1 diabetes and suggests that smoking type 1 diabetic patients have a high risk of nonaneurysmal sah. |
| PubMedID- 22688340 | The maintenance of close-to-normal blood glucose (bg) levels slows the onset and progression of long-term microvascular complications in patients with type 1 diabetes (1); therefore, the ultimate therapeutic goal of type 1 diabetes is to restore near normoglycemia (2). |
| PubMedID- 21047152 | Arterial stiffness and vascular complications in patients with type 1 diabetes: the finnish diabetic nephropathy (finndiane) study. |
| PubMedID- 24423616 | Aim: the aim of the study was to evaluate the relationship between smoking status and the incidence of microvascular complications in patients with type 1 diabetes (dm1), treated with intensive functional insulin therapy (ifit) from the onset of the disease. |
| PubMedID- 24393392 | The aim was to determine whether potential cd is associated with increased microvascular complications in patients with type 1 diabetes. |
| PubMedID- 21911773 | High prevalence of microvascular complications in adults with type 1 diabetes and newly diagnosed celiac disease. |
| PubMedID- 23813757 | The micro- and macrovascular complications of type 1 diabetes (t1d) are thought to result, primarily, from exposure of tissues to high glucose concentrations and to be reduced by intensive glycemic control (1,2). |
| PubMedID- 22442295 | Since no disease-modifying therapy is available for patients with microvascular complications of type 1 diabetes, it can be hoped that the ongoing development of a long-acting c-peptide (75) will facilitate further clinical trials and allow definition of c-peptide’s potential role in the therapy of type 1 diabetes. |
| PubMedID- 21447669 | These reports concluded that glucose variability has only a minor contribution to microvascular complications of type 1 diabetes. |
| PubMedID- 20860825 | Increased serum kallistatin levels in type 1 diabetes patients with vascular complications. |
| PubMedID- 21270199 | Our findings are also in agreement with two previous studies, which have related higher skin autofluorescence (23), as a potential marker for tissue ages accumulation, and ages levels in skin collagen (24) with incident coronary heart disease and microvascular complications in patients with type 1 diabetes, respectively. |
| PubMedID- 22701470 | Furthermore, abundant short-term evidence indicates that endothelial dysfunction precedes microvascular, as well as macrovascular complications in patients with type 1 diabetes . |
| PubMedID- 22619296 | High prevalence of microvascular complications in adults with type 1 diabetes and newly diagnosed celiac disease. |
Page: 1 2